Concordance between Ki-67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint

Identifying patients with hormone receptor-positive (HR+) early invasive breast cancer (EIBC) who benefit from adjuvant chemotherapy has improved with molecular signature tests. However, due to high cost and limited availability, alternative tests are used. The present study sought to evaluate the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Amezcua-Gálvez, Jesús Eduardo, Lopez-Garcia, Carlos A., Villarreal-Garza, Cynthia, Lopez-Rivera, Victor, Canavati-Marcos, Mauricio, Santuario-Facio, Sandra, Dono, Antonio, Monroig-Bosque, Paloma Del C., Ortiz-López, Rocío, Leal-Lopez, Andrea, Sofía Gómez-Macías, Gabriela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353786/
https://www.ncbi.nlm.nih.gov/pubmed/35949891
http://dx.doi.org/10.3892/mco.2022.2565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353786/
https://www.ncbi.nlm.nih.gov/pubmed/35949891
http://dx.doi.org/10.3892/mco.2022.2565

Ejemplares similares